Intravenous bisphosphonates

Due to the low adherence to oral bisphosphonates, intravenous bisphosphonates are the first choice. Zoledronic acid has the strongest evidence, also in age groups > 75 years. Administration of zoledronic acid to patients with a low-trauma hip fracture 2 weeks or later after surgical repair increases hip BMD, induces significant reductions in the risk of subsequent clinical vertebral, nonvertebral, and hip fractures, and reduces mortality.

Literature